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Abstract
INTRODUCTION: The overall goal of this study was to assess the utility of three-dimensional magnetic resonance
imaging (MRI) for monitoring the temporal and spatial development of experimental brain metastasis in mice.
MATERIALS AND METHODS: Brain metastatic human breast cancer cells (231-BR or 231-BR-HER2) were injected
intracardially in nude mice for delivery to the brain. Mouse brains were imaged in vivo at different time points using
a balanced steady-state-free precession (bSSFP) pulse sequence at 1.5 T. Brains were categorized into four
regions: cortex, central brain, olfactory, and posterior. The number of metastases and their volumes were quan-
tified for both cell lines. RESULTS: There was no difference in the mean number of metastases for either cell line.
The volumes of metastases in mice injected with 231-BR-HER2 cells were significantly larger than those for mice
injected with 231-BR cells. The growth rate for 231-BR-HER2 metastases was 67.5% compared with 54.4% for the
231-BR metastases. More than 50% of metastases were located in the cortex and 25% to 30% of metastases
were identified in the central brain for each time point and for mice injected with either cell line. The volumes
of metastases were significantly larger in mice with fewer metastases at end point. SIGNIFICANT CONCLUSIONS:
MRI provided a comprehensive accounting of the number and size of experimental brain metastases in the whole
mouse brain at multiple time points. This approach has provided new information about the temporal and spatial
development of metastases in the brain not possible by other histopathologic or imaging methods.
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Introduction
Traditionally, it has been reported that up to 20% of metastatic
breast cancer patients will develop brain metastases; however, this
number may be as high as 35% in patients with human epidermal
growth factor receptor 2 (HER2/neu)–expressing breast cancer [1–5].
Untreated, the median survival time is 2 to 3 months, and even with
aggressive treatment, survival is usually extended only marginally,
4 to 12 months [6]. The incidence of brain metastases in breast
cancer patients is increasing [7], especially for patients with HER2/
neu–expressing breast cancer [8]. This is attributed to patients sur-
viving primary cancers for longer periods because of improved ther-
apeutic agents that successfully treat most systemic but not brain
metastases [9,10].
To study breast cancer metastasis to the brain, mouse models have
been developed using human breast cancer cell lines [11–15]. Metas-
tases have been characterized mainly by histology, immunohisto-
chemistry, and fluorescence microscopy in these models [16–18].
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These techniques allow for measurements of the numbers of metas-
tases and the cross-sectional area of metastases and for an analysis of
cellular markers. Although these methods are able to provide detailed
molecular and morphologic information, they are limited by the
need to sacrifice the animal, and only an end point analysis is per-
mitted. In vivo imaging methods are key to a better understanding of
the progression of brain metastases.
A wealth of information can be derived about the development of
metastases from in vivo three-dimensional magnetic resonance imag-
ing (MRI). MRI is noninvasive and therefore permits multiple scan-
ning sessions to be performed to monitor the temporal features of
metastasis, whereas histology only permits a single snapshot in time.
MR images can be acquired in three dimensions, allowing the whole
brain to be analyzed in all spatial orientations and without gaps between
slices; this is unlike histologic analyses where it is a practical impossibil-
ity to analyze the whole brain, section by section. Metastases volumes
can be measured from three-dimensional MRI, which represent their
size in vivo, although similar measurements taken from histologic tissue
sections must account for shrinkage and deformation due to the chem-
ical processing. The analysis of volumes over time can provide informa-
tion about growth rates for individual metastases. Overall, MRI can
provide a much more complete picture of brain metastasis than can tra-
ditional histology.
In this study, we assessed the metastatic potential of two highly
brain metastatic human breast cancer cell lines (231-BR and 231-BR-
HER2) by quantifying the number of metastases and their volumes over
the entire brain of each mouse, at multiple time points. This study pro-
vides in vivo information about when and where metastases develop in
these models of breast cancer metastasis to the brain. This is the first
report of the in vivo spatial and temporal monitoring of the development
of experimental metastasis in the whole mouse brain by MRI.
Materials and Methods
Cell Culture
Two human breast cancer cell lines were used: (i) MDA-MB-
231BR (231-BR), which is a highly brain metastatic derivative of
the human MDA-MB-231 breast cancer cell line [11]; and (ii)
MDA-MB-231BR/HER2 (231-BR-HER2), a version of 231-BR
that is transfected with the HER2 gene [19]. Both cell lines were pre-
viously transfected with enhanced green fluorescent protein (EGFP)
under the CMV promoter using a retroviral vector (pLEGFP-C1;
BD Biosciences, Mississauga, Canada).
Cell lines were maintained in medium containing 10% fetal bovine
serum at 37°C and 5% CO2. Cells were labeled with a micrometer-
sized superparamagnetic iron oxide particle as described previously
[20]. Iron-labeled cells are visible in MR images as discrete regions
of signal void. This allowed us to identify mice that received successful
cell injections. All mice were scanned on the day of the injection and
five of the eight mice per group, which showed obvious signal voids in
the brain images, were included in the experiments. In one group of
mice, the signal voids were used to assess the early distribution of the
cancer cells in the brain after their arrest in the brain.
Animal Preparation
Nude mice (female, nu/nu, 6-8 weeks old, 18-22 g; Charles River
Laboratories, Wilmington, MA) were anesthetized with isoflurane
(2% in oxygen) and a 0.1-ml Hank’s balanced salt solution contain-
ing the cancer cells was injected into the left ventricle of the beating
heart using a 27-gauge needle, as previously described [26]. Several
experimental groups were compared.
Two groups of mice (n = 5 per group) were injected with 175,000
231-BR (mice 1-5) or 231-BR-HER2 (mice 6-10) cells and scanned
on days 19, 23, 26, and 29 after injection. On the basis of a previous
histologic analysis by Palmieri et al. [19], we expected that, at the end
point, we would observe similar total numbers of metastases for the
two cell lines but larger metastases in the brains of mice injected with
the 231-BR-HER2 cells. This in vivo longitudinal imaging experiment
was performed to expand on that histologic study by quantifying
metastasis numbers, volumes, growth rates, and spatial distributions
in the entire brain over time.
One group of mice (n = 5; mice 11-15) was injected with 50,000
231-BR-HER2 cells and scanned on day 29 after injection. Our
hypothesis was that fewer metastases would form in the brains of mice
injected with fewer cells and that the presence of fewer metastases in the
brain would impact their size and distribution.
One additional group of five mice (mice 16-20) received 175,000
231-BR-HER2 cells and were scanned on days 1 and 35 after injec-
tion. This experiment was performed to compare the distribution of
arrested cells, detected as discrete regions of signal void on day 1, with
the distribution of brain metastases at the end point.
Magnetic Resonance Imaging
Imaging was performed on a 1.5-T GE CV/I clinical MR scanner
(General Electric, Mississauga, Canada) using a custom-built gradient
coil (maximum strength = 600 mT/m and peak slew rate = 2000 T/m
per second). Before scanning, mice were anesthetized with isoflurane
(2% in oxygen) and placed in a custom-built solenoidal mouse head
radiofrequency (RF) coil (inner diameter = 1.5 cm). In vivo images
were acquired using the three-dimensional balanced steady-state-
free precession (bSSFP) pulse sequence with the following parameters:
isotropic resolution = 200 μm, repetition time = 5.4 milliseconds,
echo time = 2.7 milliseconds, flip angle = 35°, signal averages = 4,
receiver bandwidth = ±31 kHz, RF phase cycles = 4, and scan time =
62 minutes. For the mice scanned on day 1, the repetition time/echo
time was increased to 25/12.5 milliseconds to maximize the ability
to detect signal voids due to iron [21,22] and the number of signal
averages was reduced to 2 to keep the scan time under an hour.
Other parameters remained the same. Scan time was 48 minutes. Zero
filling was applied to all image data resulting in a displayed resolution of
33 × 33 × 100 μm after reconstruction.
Data Analysis
Brain metastases were counted manually in each set of images for
all mice by a single observer (M.P.); each individual mouse scan re-
sulted in 256 images. For the analysis of the distribution of metastases,
the brain was divided into four regions: the olfactory, the cortex, the
central brain, and the posterior brain. The olfactory region contained
the olfactory bulb and the anterior olfactory nucleus. The cortex region
contained the frontal cortex and the cerebral cortex. The central brain
region included the hypothalamus, the thalamus, the midbrain, the
caudate putamen, the ventral striatum, and the basal forebrain. The
posterior brain consisted of the cerebellum, the pons, and the me-
dulla. The number of metastases per region was presented as a percent-
age of the total number of metastases detected in the entire brain. This
was determined for all brain regions at each time point for mice in
each group.
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Volumes (of the brain metastases, the whole brain, and the indi-
vidual brain regions) were measured using the image analysis program
VG Studio (Volume Graphics, Heidelberg, Germany). Statistical
analyses were performed using GraphPad Prism software. Unpaired
t-tests followed by Mann-Whitney post hoc tests were conducted to
determine whether there were statistically significant differences be-
tween groups, time points, and brain regions (P < .05). Values are
presented as mean ± SE.
Results
Analysis of Whole Brain Image Data
Representative images of brain metastases (arrows) at each imag-
ing time point are shown in Figure 1 for three brain locations in a
231-BR-HER2 mouse. The image contrast for bSSFP images is related
to T 2/T 1. Metastases appear with high signal intensity in the bSSFP
images due to their high fluid content and longer T 2 compared with
the brain parenchyma. Brainmetastases were detected as early as 19 days
after injection, the first imaging time point, for all mice (Table 1). The
total number of metastases per whole brain at day 19 varied between 4
and 69 for 231-BR mice and between 17 and 64 for 231-BR-HER2
mice. At end point, there were between 49 and 165 metastases in
231-BR mice and between 34 and 202 metastases counted in the
brains of 231-BR-HER2 mice. There was no significant difference in
the mean number of metastases that developed in mice that were
injected with 175,000 231-BR or 231-BR-HER2 cells at any imaging
time point. The mean number of metastases at end point was 116 and
121, for 231-BR and 231-BR-HER2 mice, respectively.
Figure 1. Monitoring tumor growth after injection of 231-BR-HER2 cells. Representative axial bSSFP mouse brain images showing the
development of brain metastases for a mouse injected with 175,000 231-BR-HER2 cells. Each row shows three brain regions at a different
time point for the same mouse. Metastases (white arrows) appear as regions with high signal intensity compared with normal brain.
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The mean volume for all of the brain metastases in the five mice
in each group was calculated for each time point, and this is shown
in Figure 2. The mean volume was significantly larger for 231-BR-
HER2 metastases at all time points. At day 19 after injection, the
difference in the mean volumes is small but statistically significant,
and by the last imaging session, the mean volume of the metastases in
the 231-BR-HER2 mice was nearly twice that of the 231-BR mice
(0.091 mm3 for 231-BR and 0.165 mm3 for 231-BR-HER2). Hav-
ing longitudinal image data allowed us to calculate growth rates. The
volume data were fit best by an exponential function with R2 = 0.98
and R2 = 0.99 for 231-BR-HER2 and 231-BR, respectively. The
growth rate was 67.5% for 231-BR-HER2 metastases and 54.4% for
231-BR metastases.
Images from mice injected with two different numbers of 231-BR-
HER2 cells showed that the mice injected with 50,000 cells developed
far fewer metastases compared with mice that received 175,000 cells
(Table 1). The mean number of metastases at end point was 19
and 121 for mice injected with 50,000 or 175,00 cells, respectively.
The variability in the numbers of metastases was lower for mice that
developed fewer metastases; the total number of metastases at day 29
for mice that received 50,000 cells varied between 13 and 27. The
mean volume of metastases that developed in mice injected with
50,000 231-BR-HER2 cells was significantly larger than in mice
that received 175,000 231-BR-HER2 cells; 0.22 mm3 compared with
0.17 mm3, respectively.
Spatial Distribution of Metastases
In mice injected with 175,000 231-BR-HER2 or 231-BR cells,
most brain metastases were located in the cortex and central brain
regions. Figure 3 shows the percentages of metastases located in each
brain region, at each time point. At day 29, more than 90% of all
brain metastases were located in the cortex and central brain regions
for both 231-BR-HER2 and 231-BR mice. More precisely, in 231-
BR-HER2 mice at day 29 (Figure 3A), 51.9% ± 3.5% of metastases
were in the cortex, 31.1% ± 4.1% were in the central brain, 12.7% ±
4.4% were in the posterior brain, and 4.28% ± 3.7% of metastases
were located in the olfactory region. In 231-BR mice at day 29
(Figure 3B), the distribution of metastases was 62% ± 5.1%, 30% ±
2.2%, 4.5% ± 2.3%, and 3.6% ± 2.6% for the cortex, the central brain,
the posterior brain, and the olfactory regions, respectively. Asterisks in
Figure 3B indicate where there are significant differences between the
two cell lines. Over time, the percentage of 231-BR-HER2 metastases
in the cortex (Figure 3A, gray bars) decreased, as the percentage in the
olfactory and posterior brain regions increased, causing a shift in the final
distribution. The percentage of metastases in the cortex was significantly
higher for the 231-BR line compared with the 231-BR-HER2 cell line,
Table 1. Summary of the Number of Metastases in Mice Injected with 231-BR or 231-BR-HER2 Cells.
Mouse 231-BR (175,000) Mouse 231-BR-HER2 (175,000) Mouse 231-BR-HER2 (50,000)
Day 19 Day 23 Day 26 Day 29 Day 19 Day 23 Day 26 Day 29 Day 29
1 28 61 102 122 6 19 31 36 37 11 16
2 33 48 114 — 7 55 134 — — 12 27
3 4 17 N/A 49 8 35 110 202 — 13 26
4 20 64 84 130 9 64 135 191 197 14 13
5 69 99 N/A 165 10 17 25 28 34 15 13
Mice 1 to 5 received 175,000 231-BR cells, mice 6 to 10 received 175,000 231-BR-HER2 cells, and mice 11 to 15 received 50,000 231-BR-HER2 cells. The metastases were counted manually by
assessing each image slice covering the whole mouse brain for sets of images obtained at each time point. A dash indicates that the mouse was killed before imaging could take place at that time point
because of its health status. The numbers in boxes shaded gray indicate the number of metastases at the end point. The mean number of metastasis at end point was 116 for 175,000 231-BR, 121 for
175,000 231-BR-HER2, and 19 for 50,000 231-BR-HER2.
N/A indicates not applicable.
Figure 2. Mean metastases volumes in the whole brain for 231-BR-HER2 and 231-BR mice. At each time point, the mean metastasis
volume was calculated for all metastases in all mice in each group. The mean volume was significantly greater for 231-BR-HER2 mice
(gray bars) compared with 231-BR mice (white bars) at every time point (*P < .05). The mean volumes increased between each time
point for both cell lines (significant at P < .05). An exponential growth curve fits the data best for each cell line. The growth rates were
67.5%, with R2 = 0.98 for 231-BR-HER2 metastases (solid line) and 54.4% with R2 = 0.99 for 231-BR metastases (dashed line).
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at days 23, 26, and 29. The percentage of metastases in the posterior
region was significantly higher for the 231-BR-HER2 cell line at all
time points. The percentage of metastases in the central brain was sig-
nificantly higher for the 231-BR-HER2 cell line at day 23.
To determine whether the number of brain metastases that devel-
oped in each brain region was merely related to the size of the prede-
fined brain regions (i.e., there were more metastases just because the
region is larger), the volumes of the four brain regions were calculated
(Table 2). The individual brain region volumes were as follows: cortex =
141.5 mm3, central brain = 143.1 mm3, posterior brain = 104.8 mm3,
and olfactory region = 22.4 mm3. The mean volume of the whole brain
was 411.5 mm3. Therefore, the cortex occupied approximately 34%
of the whole brain; the central brain, 35%; the posterior brain, 26%;
and the olfactory region, 5% (Table 2). The mean volumes of the
cortex and the central brain were nearly equal (141.5 and 143.1 mm3,
respectively) despite large differences in the numbers of metastases. The
mean percentage of metastases in the cortex and central brain at day 29
was significantly different for both cell lines; 62% versus 30% for 231-
BR and 51.9% versus 31.1% for 231-BR-HER2. Despite very large
differences in the mean volumes of the posterior and olfactory regions
(104.8 and 22.4 mm3, respectively), there was no significant difference
in the percentages of metastases in these regions at day 29 for either cell
line. Furthermore, although the volume of the posterior brain region
represents a quarter of the whole brain volume, only 12.7% and 4.5%
of metastases from 231-BR-HER2 and 231-BR mice, respectively, were
located in this region at day 29 (Figure 3 and Table 2). This analysis
indicates that the size of the brain region is not the main determinant
of the number of metastases developing within it.
Figure 4 shows the mean tumor volumes at each time point for
each of the different brain regions. We compared the volumes of
metastases in mice that received 175,000 231-BR (white bars) or
231-BR-HER2 (gray bars) cells. In the cortex, the mean tumor volume
was significantly larger for 231-BR-HER2 mice compared with 231-BR
mice at days 23, 26, and 29 after injection. In the central brain region,
this was the case for all time points. The trend was similar for the pos-
terior brain region, but no significant differences were measured for the
olfactory regions.
We also looked to see whether the volumes of metastases were
different in the various brain regions. There were notable differences
at some time points. For example, at days 19 and 26, 231-BR-HER2
metastases were significantly larger in the central brain compared
with those in the cortex and olfactory regions. At days 19 and 26,
231-BR metastases in the olfactory region were significantly larger
than all other brain regions. Interestingly, by day 29, which is a typical
end point for this sort of study, there were no differences detected in
metastases volumes between the brain regions.
We were also able to assess growth rates for metastases within each
brain region. The data for volume over time were reliably fit by an ex-
ponential trend line for all regions for 231-BR-HER2 metastases, except
the olfactory region. In the olfactory region, a linear function best fit the
data; the growth rate (27%) was also much lower than that of metastases
in the other brain regions. Similarly, growth of the 231-BR metastases
was exponential, except for that in the posterior region where neither
linear nor exponential fits resulted in a sufficiently high R2 value.
Comparing Voids Detected on Day 1 with Metastases Detected
on Day 35
We imaged one group of mice injected with 175,000 231-BR-
HER2 cells on days 1 and 35 to compare the distribution of the signal
Figure 3. Relative distribution of metastases in the brain for 231-
BR-HER2 and 231-BR mice. The percent distribution of tumors in
each brain region is shown for all time points for 231-BR-HER2
mice (A) and 231-BR mice (B). The asterisks denote a statistically
significance difference (P < .05) between the two cell lines.
Table 2. Summary of the Percentages of Metastases per Brain Region at Day 29 and the Corresponding Growth Rates for 231-BR and 231-BR-HER2 Mice.
Brain Regions Volume (mm3) % Whole Brain % Metastases at Day 29 Growth Rates (%)
231-BR 231-BR-HER2 231-BR 231-BR-HER2
Cortex 141.5 ± 9.1 34 62.0 ± 5.1*,† 51.9 ± 3.5† 50 (exp, R2 = 0.95) 65 (exp, R2 = 0.97)
Central brain 143.1 ± 6.8 35 30.0 ± 2.2 31.1 ± 4.1 50 (exp, R2 = 0.96) 67 (exp, R2 = 0.99)
Posterior 104.8 ± 4.1 26 4.5 ± 2.3* 12.7 ± 4.4 N/A 72 (exp, R2 = 0.98)
Olfactory 22.4 ± 3.4 5 3.6 ± 2.6 4.28 ± 3.7 65 (exp, R2 = 0.98) 27 (line, R2 = 0.97)
The volumes of the four brain regions (cortex, central, posterior, and olfactory) were measured and the percentage of the whole brain that they occupy was calculated. The percentages of metastases in
each of these brain regions were determined for each cell line.
The best fit for the growth curves, the growth rates, and the R2 were measured from the data in Figure 4. The R2 value indicates the goodness of the fit (with R2 = 1 meaning a perfect fit), exp = indicates
an exponential growth, line = linear growth.
*Significant difference between the two cell lines (P < .05).
†Significant difference between the cortex and central brain regions (P < .05).
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voids visible on day 1, due to the arrest of iron-labeled cells, with the
distribution of brain metastases at end point (Figure 5). On day 1,
approximately 50% of the void volume was located in the cortex,
28% in the central brain, 17% in the posterior brain, and 5% in the
olfactory region (Figure 5B). On day 35, approximately 50% of the
metastases were located in the cortex, 40% in the central brain, 8%
in the posterior brain, and 2% in the olfactory region (Figure 5C).
The ratio of the “number of tumors at end point/void volume on
day 1” was 1 for the cortex, 1.45 for the central brain region, and
0.45 and 0.24 for the posterior and olfactory brain regions, respec-
tively. This suggests that a smaller proportion of the cells that arrest
in the brain for the posterior and olfactory regions go on to form
metastases compared with the cells that arrest in the cortex and cen-
tral brain regions and that both the initial arrest and the survival of
cells in particular brain regions is important.
Discussion
In the current work, we demonstrate how MRI can be used to study
cancer progression with high spatial resolution, excellent soft tissue
contrast, and with the ability to image an entire organ longitudinally
over time. We used MRI to compare brain metastases due to two
different human breast cancer cell lines; 231-BR, which is a brain
metastatic derivative of the parental MDA-MB-231 cell line, estab-
lished by Yoneda et al. [11], and 231-BR-HER2, a version of this cell
line that was transfected with HER2 by Palmieri et al. [19]. Many
studies indicate that HER2 overexpression correlates with more
aggressive disease [23], increased metastatic potential [24], and a
poorer prognosis [25] in patients with breast cancer. We also compared
metastases resulting from the injection of two different cell numbers
for 231-BR-HER2.
The three-dimensional, high-resolution nature of MRI allowed us
to quantify the total numbers of metastases in the whole brain for
each mouse at every imaging time point. A large amount of data
can be collected from relatively small numbers of animals this way;
we counted 1184 metastases in the end point images of mice 1 to
10 alone. We found that there were similar numbers of metastases
observed in the brain images for both 231-BR and 231-BR-HER2 cell
lines; however, 231-BR-HER2 metastases developed significantly
larger volumes than 231-BR metastases.
Palmieri et al. [19], who originally created the 231-BR-HER2 cell
line, and who previously compared brain metastases due to 231-BR
and 231-BR-HER2 through a histologic analysis, reported similar
findings. The advantages of using MRI are that we were able to
interrogate the whole brain at more than a single time point and to
calculate the volumes of the MRI detectable brain metastases. By
comparison, Palmieri et al. assessed one hemisphere of the brain at
end point and used a grid to rank metastases visible in hematoxylin
and eosin–stained sections as either large (>50 μm2) or small (<50 μm2).
MRI provided additional information that was not possible to glean
from a conventional histologic study. The longitudinal data showed
that new metastases appeared at each imaging time point, for both cell
lines, up to and including the end point scans. Longitudinal MRI also
allowed us to look at growth rates and showed that growth rate for 231-
BR-HER2 metastases was greater than that for 231-BR. Importantly,
MRI revealed that metastases due to the 231-BR-HER2 cell line were
significantly larger than those from 231-BR from the earliest time point
Figure 4.Mean metastases volumes in each brain region for 231-BR-HER2 and 231-BR mice. Mean volumes for metastases due to 231-
BR-HER2 (gray bars) and 231-BR (white bars) cells in the cortex, central brain, posterior brain, and the olfactory brain region for each
imaging time point. *Statistical significance (P < .05) between the two cell lines.
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they were detectable by MRI (day 19). These data provide additional
evidence that HER2 overexpression has a pronounced effect on breast
cancer metastatic growth in the brain and suggest that whatever medi-
ates HER2 aggressiveness happens early.
Another interesting finding was our observation that, for both
231-BR and 231-BR-HER2 cell lines, animals that developed fewer
brain metastases had larger metastases. This may be related to the fact
that there is more room within the intracranial space for a smaller
number of metastases to grow [26]. Likewise, growth may be limited,
when there are large numbers of metastases, by competition for re-
sources. Kuang et al. [27] used detailed mathematical modeling to
demonstrate the potential growth limitations that a tumor may expe-
rience when competing for resources with the surrounding healthy
tissue. Our observation of larger metastases in the brains of mice with
fewer metastases is a novel finding that was possible because of our
whole brain imaging approach.
The main limitation of MRI when compared with histology is
spatial resolution. The smallest metastasis detected with MRI in this
study was 0.001 mm3 (this represent a three-dimensional image
voxel of 100 × 100 × 100 μm). Still, most histologic studies that have
looked at brain metastases in stained sections consider a micrometas-
tasis to be on the order of 50 μm in diameter or less [19]. A single
micrometastasis may therefore go undetected or, a closely spaced col-
lection of multiple micrometastases may appear as a single metastasis,
using our MRI protocols. Furthermore, the MRI described in this
study does not provide any molecular information, whereas immuno-
histochemistry can. However, one of the main advantages of MRI is
its noninvasive nature, which allows for multiple time point analyses
on live animals. Thus, MRI and microscopy are complementary and
together can provide information at the small animal, cellular, and
molecular levels.
Three-dimensional MRI also allowed us to examine the full spatial
distribution of metastases in the brain. Overall, we found that a larger
percentage of the metastases were located in the cortex and central
brain regions, with smaller numbers of metastases in the olfactory
and posterior brain regions, for both cell lines. Our findings are sim-
ilar to those of Fitzgerald et al. [28] who reported a nonrandom
distribution of brain metastases for 231-BR cells in nude mice. They
identified the locations of metastases for each mouse in a binary fash-
ion, by indicating that they were, or were not, present in stained sec-
tions from a number of brain locations at end point. In contrast,
three-dimensional MRI permitted a comprehensive and quantitative
assessment of the percentages of metastases in each of the different
brain regions, and changes in these patterns with time. MRI revealed
that, for the 231-BR cell line, the distribution of brain metastases
remained fairly uniform over time. However, for the 231-BR-HER2
cell line, the proportion of metastases located in the posterior brain
region increased with time, reducing the percentage of the cortex occu-
pied by metastases, with the result that, at days 23, 26, and 29 after
injection, the number of metastases that were detected in the cortex
was greater for the 231-BR cell line. This type of analysis within the
same mouse is not possible by histology.
To the best of our knowledge, this study is the first to provide
quantitative imaging data on the temporal and spatial development
of brain metastases in the mouse. Ribot et al. [22] have previously
used the 231-BR brain metastasis model in nude mice to develop
the bSSFP imaging sequence for the detection of both metastasis
and iron-labeled cells. The blood-brain permeability associated with
developing 231-BR brain metastases was studied by Percy et al. [29].
Song et al. [30] have established a nude rat model of breast cancer
brain metastasis using the 231-BR cell line, transfected with the lucif-
erase gene, and evaluated it using MRI (of the brain) and biolumines-
cence imaging (BLI). The percentages of animals with metastases in the
brain, the spinal cord, the visceral organs, or the bone were determined
through the analysis of MRI, BLI, and histology. Unexpected skeletal
metastases in the spine were reported for the first time, pointing to the
Figure 5. Distribution of signal voids on day 1 after injection (A) and of metastases at day 35 (B) for a group of 231-BR-HER2 mice. The
void volume and the number of metastases were measured for each brain region. *Statistical significance (P < .05) between the void
and the metastasis distribution.
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value of whole body and multimodality imaging. Brain metastases,
detected byMRI and histology, were not visible by BLI, indicating that
this imaging modality is not optimal for brain studies.
Palmieri et al. [19] used fluorescence imaging to detect the EGFP
associated with the 231-BR-HER2 cell line in excised mouse brains.
Although they reported a general trend of increasing fluorescent
metastases with greater HER2 overexpression, quantification of these
images was not possible because of low resolution, autofluorescence,
and overlap of the fluorescent signal from nearby metastases.
By prelabeling cancer cells with iron oxide nanoparticles, we could
visualize the distribution of these cells throughout the whole, intact
brain soon after their arrest. Previous work in our laboratory has vali-
dated that the discrete regions of signal void, detected by MRI at day 1,
represent individual iron-labeled cells or small clusters of cells trapped
in brain capillaries [31]. We quantified the volume of signal loss in each
brain region on day 1 and compared this with the distribution of me-
tastases in these brain regions at day 35. This experiment provided
unique information about cancer cells in the brain of the same animals,
at two time points after their injection, which is not possible with any
other method. This analysis revealed that, in the cortex, the number
of metastases that develop was directly related to the number of cells
arresting there. This was similar for the central brain region, although
not as linear. However, in the brain regions where far fewer metastases
developed, the olfactory and posterior regions, the trend was reversed.
This suggests that the microenvironment in the posterior and olfactory
regions does not support the growth of brain metastases as well as the
cortex and central brain regions. Previous studies have shown that the
initial arrest of cancer cells in the brain is related to blood flow [28] and
the presence of gray matter/white matter junctions [32]. Our results
support these notions because the cortex contains the most blood ves-
sels and the highest number of gray matter/white matter junctions
when compared with the other brain regions we examined [32].
In this study, bSSFP images were acquired on a clinical system
along with a custom-built high-performance gradient insert, which
allowed for the higher resolution needed for mouse imaging. The
bSSFP sequence is widely available on clinical scanners and gradient
coils on modern clinical scanners can reach 50 mT/m, which is ap-
proximately the gradient strength we used in these studies. To date,
bSSFP has been used mainly for cardiac imaging [33,34]. However,
bSSFP is finding more use clinically for improving brain lesion detec-
tion and treatment. Pastel et al. [35] demonstrated that, because of its
high spatial resolution, bSSFP was able to help differentiate small
pineal cysts from tumors. Xie et al. [36] have noted the potential of
bSSFP to help delineate fine brain structures in endonasal surgical
treatment of tumors, once again because of its high resolution. In
the future, the application of this technique on humans could lead
to new information about breast cancer metastases to the brain, lead-
ing to adapted therapy strategies.
Conclusions
MRI is a powerful method for investigating preclinical models of
cancer and metastasis. We have shown that longitudinal imaging
of developing brain metastases can provide abundant data on the
numbers and sizes of metastases as well as the rate of growth of
brain metastases. This technology will provide new information
about metastasis in the brain by allowing individual metastases to be
scrutinized as they develop over time or as they change in response
to treatment.
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